10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q3 2019

Filing Information

Form Type	10-Q
Accession Number	`0001532176-19-000034`
Period End Date	20190930
Filing Date	20191105
Fiscal Year	2019
Fiscal Period	Q3
XBRL Instance	regn-093019x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 69 Income Statement 84 Cash Flow Statement 58 Stockholders Equity 55

Balance Sheet 69 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.09B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.38B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.47B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.34B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$1.49B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.72B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$2.03B	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$226.40M	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$345.40M	USD	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	3.99M	shares	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$286.90M	USD	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	4.17M	shares	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$293.10M	USD	Point-in-time
Inventories	`InventoryNet`	$1.34B	USD	Point-in-time
Inventories	`InventoryNet`	$1.15B	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$243.30M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$226.90M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$7.11B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$6.45B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.75B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$3.11B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.77B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.58B	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$828.70M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$808.30M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$137.90M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$127.40M	USD	Point-in-time
Total assets	`Assets`	$13.94B	USD	Point-in-time
Total assets	`Assets`	$11.73B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$218.20M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$335.60M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$821.10M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$772.10M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.77B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.44B	USD	Point-in-time
Finance lease liabilities	`FinanceLeaseLiabilityNoncurrent`	$712.70M	USD	Point-in-time
Finance lease liabilities	`Capitalandfacilityleaseobligationsnoncurrent`	$708.50M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$273.00M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$361.70M	USD	Point-in-time
Total liabilities	`Liabilities`	$3.43B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.98B	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.91B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$4.39B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$6.59B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$5.25B	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$16.50M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-12.30M	USD	Point-in-time
Treasury Stock, at cost; 4,167,018 shares in 2019 and 3,990,021 shares in 2018	`TreasuryStockValue`	$396.40M	USD	Point-in-time
Treasury Stock, at cost; 4,167,018 shares in 2019 and 3,990,021 shares in 2018	`TreasuryStockValue`	$488.40M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.19B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$8.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$10.50B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.87B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.14B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.57B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.76B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$9.44B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$11.73B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$13.94B	USD	Point-in-time

Income Statement 84 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.05B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$5.69B	USD	3 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.66B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.78B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$2.35B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.58B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$663.40M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$557.00M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.25B	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$419.90M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$1.06B	USD	3 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$369.20M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.04B	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$2.97B	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$4.16B	USD	3 Qtrs
Total expenses	`CostsAndExpenses`	$1.31B	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$626.90M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.53B	USD	3 Qtrs
Income from operations	`OperatingIncomeLoss`	$738.50M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.82B	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$16.40M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$37.80M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$28.70M	USD	3 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$81.80M	USD	3 Qtrs
Interest expense	`InterestExpense`	$7.40M	USD	1 Quarter
Interest expense	`InterestExpense`	$23.50M	USD	3 Qtrs
Interest expense	`InterestExpense`	$20.80M	USD	3 Qtrs
Interest expense	`InterestExpense`	$7.80M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$61.00M	USD	3 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$9.00M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$30.00M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$5.20M	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$768.50M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.88B	USD	3 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$635.90M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.54B	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$215.50M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$98.90M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$253.30M	USD	3 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$41.20M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$477.90M	USD	1 Quarter
Net income	`NetIncomeLoss`	$594.70M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$12.12	USD	3 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$6.12	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$5.50	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$15.06	USD	3 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$14.14	USD	3 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.17	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.86	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$11.54	USD	3 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	108.00M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.40M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	109.20M	shares	3 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.80M	shares	3 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.10M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.20M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.80M	shares	3 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.70M	shares	3 Qtrs
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$477.90M	USD	1 Quarter
Net income	`NetIncomeLoss`	$594.70M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$31.50M	USD	3 Qtrs
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-6.90M	USD	3 Qtrs
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized gain (loss) on debt securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$700.00K	USD	1 Quarter
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-2.70M	USD	3 Qtrs
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-300.00K	USD	1 Quarter
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$2.40M	USD	3 Qtrs
Unrealized (loss) gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$300.00K	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.62B	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$670.30M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.35B	USD	3 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$595.70M	USD	1 Quarter

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$477.90M	USD	1 Quarter
Net income	`NetIncomeLoss`	$594.70M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$105.40M	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$156.00M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$330.80M	USD	3 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$300.70M	USD	3 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$-113.20M	USD	3 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$82.70M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$33.50M	USD	3 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$110.00M	USD	3 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$228.60M	USD	3 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$460.90M	USD	3 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$281.60M	USD	3 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$227.20M	USD	3 Qtrs
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-21.20M	USD	3 Qtrs
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$87.80M	USD	3 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$375.80M	USD	3 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-29.50M	USD	3 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$179.90M	USD	3 Qtrs
Increase in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$119.90M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-157.70M	USD	3 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$318.80M	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.47B	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.64B	USD	3 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$2.83B	USD	3 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$1.53B	USD	3 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$1.31B	USD	3 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$644.10M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$297.60M	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$290.60M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$10.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	-	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.82B	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.20B	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$87.40M	USD	3 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$163.50M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$77.10M	USD	3 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$40.50M	USD	3 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$4.40M	USD	3 Qtrs
Repurchases of Common Stock	`PaymentsForRepurchaseOfCommonStock`	$29.40M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$5.90M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$93.60M	USD	3 Qtrs
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-82.90M	USD	3 Qtrs
Net (decrease) increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$275.10M	USD	3 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.40B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.10B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.20M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.48B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.40B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.10B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.20M	USD	Point-in-time

Stockholders Equity 55 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$7.19B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$10.50B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$7.87B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$6.14B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$6.57B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$8.30M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$13.90M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$57.30M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$140.90M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$19.80M	USD	1 Quarter
Issuance of Common Stock in connection with exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$13.60M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$100.00K	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$31.90M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$29.70M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$10.70M	USD	1 Quarter
Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$45.20M	USD	1 Quarter
Issuance/distribution of Common Stock in connection with 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$-700.00K	USD	1 Quarter
Issuance/distribution of Common Stock in connection with 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$11.70M	USD	1 Quarter
Issuance/distribution of Common Stock in connection with 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$10.50M	USD	1 Quarter
Issuance/distribution of Common Stock in connection with 401(k) Savings Plan	`StockIssuedDistributedDuringPeriodValueEmployeeBenefitPlan`	$6.00M	USD	1 Quarter
Repurchases of Common Stock from Sanofi	`TreasuryStockValueAcquiredCostMethod`	$54.00M	USD	1 Quarter
Repurchases of Common Stock from Sanofi	`TreasuryStockValueAcquiredCostMethod`	$37.60M	USD	1 Quarter
Repurchases of Common Stock from Sanofi	`TreasuryStockValueAcquiredCostMethod`	$42.60M	USD	1 Quarter
Repurchases of Common Stock from Sanofi	`TreasuryStockValueAcquiredCostMethod`	$48.70M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$85.80M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$109.20M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$113.10M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$114.80M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$116.50M	USD	1 Quarter
Stock-based compensation charges	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$112.70M	USD	1 Quarter
Net income	`NetIncomeLoss`	$461.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.32B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$669.60M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.62B	USD	3 Qtrs
Net income	`NetIncomeLoss`	$477.90M	USD	1 Quarter
Net income	`NetIncomeLoss`	$594.70M	USD	1 Quarter
Net income	`NetIncomeLoss`	$193.10M	USD	1 Quarter
Net income	`NetIncomeLoss`	$551.40M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$-9.70M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$1.10M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$4.10M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$15.10M	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$700.00K	USD	1 Quarter
Other comprehensive gain (loss), net of tax	`OtherComprehensiveIncomeLossNetOfTax`	$13.00M	USD	1 Quarter
Ending Balance	`StockholdersEquity`	$7.19B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$8.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$10.50B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$7.87B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$6.14B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$6.57B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.76B	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$9.44B	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.